O'Neill Gilmore Neil's Form 4 filing
Editas Medicine, Inc. (EDIT) · filed Mar 5, 2024
- Accession no.
- 0001650664-24-000015
- Filed
- Mar 5, 2024
- Trade date
- Mar 2-5, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $733.1K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Neill Gilmore NeilCIK 0001742084 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2024 | Common Stock | AGrant or awardAcquired | +130,700 | $0.00 | $0 | 260,869 | Direct | |
| Mar 2, 2024 | Common Stock | AGrant or awardAcquired | +72,213 | $0.00 | $0 | 333,082 | Direct | |
| Mar 2, 2024 | Common Stock | AGrant or awardAcquired | +72,212 | $0.00 | $0 | 405,294 | Direct | |
| Mar 5, 2024 | Common Stock | SSaleDisposed | −77,824 | $9.42F5 | −$733,102.08 | 327,470 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2024 | Common Stock | AGrant or awardAcquired | +392,100 | $0.00 | $0 | 392,100 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.